Vecura Manufacture

Vecura – An Infrastructure for Development and Manufacturing of ATMPs.

The project involves development of three different GMP-compliant processes used in manufacturing of ATMPs.

Period: 09/2021 – 08/2023

Lead: Pontus Blomberg, Karolinska University Hospital

Involved partners: Vecura/Karolinska University Hospital, Karolinska Institutet, Cytiva, NEOGAP, XNK Therapeutics

1. Subproject – Expansion of GMP Compliant Tumor Infiltrating Lymphocytes (TILs) in Xuri bioreactor (continuation)
2. Subproject – Expansion of GMP-compliant adaptive T-cells in bioreactor
   • This project aims towards the establishment of an automated closed system for manufacturing of adoptive T-cells for cancer treatment.
   • Time period: 09/2021 – 08/2023.
   • Lead: Pontus Blomberg, Karolinska University Hospital.
   • Involved partners: NEOGAP AB, VivaBioCell
3. Subproject – Cell processing of NK-cells using Sepax cell processing instrument
   • The project will explore the feasibility of the applications of the Sepax C-Pro in the CellProtect work-flow including procurement of cells, thawing and resuspension and harvest from bioreactor.
   • Time period: 09/2021 – 08/2023.
   • Lead: Pontus Blomberg, Karolinska University Hospital.
   • Involved partners: XNK AB, Cytiva AB

Publications

“Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination.”

“Human serum albumin as a clinically accepted cell carrier solution for skin regenerative application.”

“Karolinska Institutet Human Embryonic Stem Cell Bank.”

“Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.”

“Gene therapy – from idea to reality” (Swedish)

“A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.”